Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730787 | 0.91 | HDAC3 (0.41) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL28931791 | 0.80 | SLC9A1 (0.42) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL10072556 | 0.77 | TSHR (0.51) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL28375728 | 0.76 | TSHR (0.39) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL8401072 | 0.74 | TSHR (0.49) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL798347 | 0.72 | TSHR (0.58) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL29389351 | 0.72 | TSHR (0.61) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL736439 | 0.72 | TSHR (0.61) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL14501845 | 0.71 | TSHR (0.49) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL4199149 | 0.71 | CHRM2 (0.49) | TSHRNPSR1RXFP1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632934-B1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-11-30 | — | — | EP | claimed |
| EP-2054368-B1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8299054-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-7727978-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2054368-A2 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-25 | — | — | US | disclosed |
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| WO-2008024892-A2 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD17B1, HSD11B2 | SLC9A1 343/4885KEAP1 2041/4885TSHR 4082/4885 |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD17B1, HSD11B2 | SLC9A1 343/4885KEAP1 2041/4885TSHR 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.